Reply to E.R.S. Cliff et al
- 1 April 2023
- journal article
- letter
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (10), 1951-1952
- https://doi.org/10.1200/jco.22.02691
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Prevention of infections including vaccination strategies in multiple myelomaAmerican Journal of Hematology, 2022
- Risk factors for severe infection and mortality In patients with COVID‐19 in patients with multiple myeloma and AL amyloidosisAmerican Journal of Hematology, 2022
- A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple MyelomaJournal of Clinical Oncology, 2022
- Teclistamab in Relapsed or Refractory Multiple MyelomaThe New England Journal of Medicine, 2022
- Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myelomaBlood Advances, 2022
- Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myelomaLeukemia, 2021
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label studyThe Lancet, 2021
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple MyelomaThe New England Journal of Medicine, 2021
- Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data setBlood, 2020
- Multiple myeloma and COVID-19Leukemia, 2020